Bull Pharmachem
Bull Pharmachem
Kalbadevi, Mumbai, Maharashtra
GST No. 27AKFPJ6383E1Z2
TrustSEAL Verified
Call 08048419840 88% Response Rate
SEND EMAIL

Miscellaneous

Leading Exporter of finpecia (finasteride 1mg), propecia (finasteride 1mg), nebido (testosterone undecanoate), scapho (secukinumab 150 mg) and beovu (brolucizumab-dbll 6mg) from Mumbai.

Finpecia (Finasteride 1mg)

Finpecia (Finasteride 1mg)
  • Finpecia (Finasteride 1mg)
  • Finpecia (Finasteride 1mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
Brand NameFINPECIA
ManufacturerCipla Ltd
TreatmentIncrease Hair Growth
Packaging Size100 Tablets
Packaging TypeStrips
Strength1mg
FormOral
Usage/ApplicationHospital

Finpecia (Finasteride 1mg)Tablet is used to treat hair loss in men. It is used to increase hair growth and prevent further hair loss with male pattern baldness (gradual thinning of hair with receding hairline or thinning on the top of the head). Finpecia Tablet is to be taken by mouth with or without food. The dose and duration of the medicine should be taken as per prescription. An overdose of it may cause harm to your health. It is better to take the medicine at the same time each day and it must be swallowed as a whole. It may take some time for the medicine to act upon the symptoms, so it is important to take the medicine regularly. The course of the treatment should be completed for better efficacy of the medicine. This medicine is usually well tolerated. However, it may cause some mild sexual side effects such as low decreased libido, erectile dysfunction, and ejaculation disorder. Some people may also experience allergic reactions such as itching, rashes, and swelling of the lips or face. If you experience any of these side effects, consult your doctor without delay. Before starting the treatment, it is important to tell your doctor if you are taking any medication for any health condition. USES OF FINPECIA TABLET Treatment of Hair loss BENEFITS OF FINPECIA TABLET In Treatment of Hair loss Finpecia Tablet is a medicine used to treat common hereditary hair loss. It prevents further hair loss and helps hair to regrow. It stops production of a hormone that causes excessive hair fall or baldness and also increases hair growth. It is considered as a safe medicine. Regrowth of hair can be beneficial to your mood, self-esteem as well as your appearance, but you need to use it regularly to get the benefits. SIDE EFFECTS OF FINPECIA TABLET Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them Common side effects of Finpecia Decreased libido Erectile dysfunction Ejaculation disorder HOW TO USE FINPECIA TABLET Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Finpecia Tablet may be taken with or without food, but it is better to take it at a fixed time. HOW FINPECIA TABLET WORKS Finpecia Tablet is a 5-alpha reductase inhibitor. It blocks the body's production of a male hormone in the scalp that stops hair growth, thereby reversing the balding process and preventing further hair loss. SAFETY ADVICE warnings Alcohol CONSULT YOUR DOCTOR It is not known whether it is safe to consume alcohol with Finpecia Tablet. Please consult your doctor. warnings Pregnancy UNSAFE Finpecia Tablet is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby. warnings Breastfeeding CONSULT YOUR DOCTOR Information regarding the use of Finpecia Tablet during breastfeeding is not available. Please consult your doctor. Finpecia Tablet is not indicated in women. warnings Driving SAFE Finpecia Tablet does not usually affect your ability to drive. warnings Kidney SAFE IF PRESCRIBED Finpecia Tablet is safe to use in patients with kidney disease. No dose adjustment of Finpecia Tablet is recommended. warnings Liver CONSULT YOUR DOCTOR There is limited information available on the use of Finpecia Tablet in patients with liver disease. Please consult your doctor. However, Finpecia Tablet should be used with caution in these patients.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Propecia (Finasteride 1mg)

Propecia (Finasteride 1mg)
  • Propecia (Finasteride 1mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity28 Strip
Packaging Size28 Tablets
BrandPROPECIA
ManufacturerMSD
FormTablet
TreatmentBenign Prostatic Hyperplasia
Prescription/Non prescriptionPrescription
Usage/ApplicationPersonal
CompositionFinasteride
Shelf Life2 Years

Propecia (Finasteride 1mg) is a prescription medicine used to treat the symptoms of benign prostatic hyperplasia (BPH), male pattern hair loss (androgenic alopecia). Propecia may be used alone or with other medications. Propecia belongs to a class of drugs called 5-Alpha-Reductase Inhibitors. It is not known if Propecia is safe and effective in children. What are the possible side effects of Propecia? Propecia may cause serious side effects including: breast lumps, breast pain or tenderness, nipple discharge, and any other breast changes Get medical help right away, if you have any of the symptoms listed above. The most common side effects of Propecia include: loss of interest in sex, impotence, trouble having an orgasm, and abnormal ejaculation Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Propecia. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. DESCRIPTION PROPECIA (finasteride) tablets contain finasteride as the active ingredient. Finasteride, a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). PROPECIA® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY. Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women. DOSAGE AND ADMINISTRATION PROPECIA may be administered with or without meals. The recommended dose of PROPECIA is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically. Withdrawal of treatment leads to reversal of effect within 12 months. HOW SUPPLIED Dosage Forms And Handling PROPECIA tablets (1 mg) are tan, octagonal, film-coated convex tablets with “stylized P” logo on one side and PROPECIA on the other. Storage And Handling No. 6642 — PROPECIA tablets, 1 mg, are tan, octagonal, film-coated convex tablets with “stylized P” logo on one side and PROPECIA on the other. They are supplied as follows: NDC 0006-0071-31 bottles of 30 (with desiccant) NDC 0006-0071-54 PROPAK bottles of 90 (with desiccant). Storage And Handling Store at room temperature, 15-30°C (59-86°F). Keep container closed and protect from moisture. Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets are not broken or crushed [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and Patient Counseling Information].
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

NEBIDO (Testosterone Undecanoate)

NEBIDO (Testosterone Undecanoate)
  • NEBIDO (Testosterone Undecanoate)
  • NEBIDO (Testosterone Undecanoate)
Ask For Price
Product Price :Get Latest Price

Product Details:

Brand NameNEBIDO
ManufacturerBayer
Packaging TypeBottle
Packaging Size1 Vial
Dose1000 Mg
Quantity Per Pack1 Vial
Shelf Life2 Years
Deals inThird Party Manufacturing
DeliveryImmediate
Storage Temperature30 DegreeC.
TreatmentMale Hypogonadism.

Nebido is a testosterone preparation for intramuscular injection. One ampoule contains 1,000 mg testosterone undecanoate in 4 mL oily vehicle (castor oil). The shelf life of Nebido is 5 years. Nebido is the first long-acting testosterone injection for the treatment of male hypogonadism. Nebido contains 1,000 mg of testosterone undecanoate in a 4 mL oily solution in an innovative formulation which offers a superior kinetic profile. After administration of Nebido, testosterone levels remain within the physiological range for about 12 weeks. Therefore, only 4 injections per year are required in long-term testosterone therapy. Nebido avoids unphysiological peaks and troughs in serum testosterone. It has been established in clinical studies that testosterone levels are already back to the normal range 3 days after the first administration of Nebido. On testosterone concentrations in the blood Pharmacokinetic studies have demonstrated that testosterone levels are restored to the physiological range within 3 days after the first administration of Nebido. With an interval between injections of about 12 weeks, testosterone concentrations remain constantly within the physiological range. The first dosing interval may be reduced to six weeks, which enables steady state testosterone levels to be achieved more rapidly. On clinical symptoms Nebido improves the symptoms associated with testosterone deficiency. Nebido exerts a positive effect on sexual function and mood, increases muscle mass and muscle strength and decreases body fat. The most frequent side effects observed with Nebido are reactions at the injection site. These reactions are generally mild and transient. All other side effects observed in isolated cases are typical of testosterone (such as diarrhoea, joint pain, sweating, headache, acne, chest pain and gynaecomastia). Pulmonary oil microembolism has been observed after injection during routine clinical practice and in rare cases lead to signs and symptoms such as cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paraesthesia, or syncope. These reactions may occur during or immediately after the injection and are reversible. The patient should therefore be observed during and immediately after each injection in order to allow for early recognition of possible signs and symptoms of pulmonary oily microembolism. Treatment is usually supportive, e.g. by administration of supplemental oxygen. Attention should be paid to the following recommendations for dosage: First and second administration of Nebido 6 weeks apart. Subsequently, depending on the needs of the individual patient, an interval of about 12 weeks is recommended. The first interval between injections may also be shortened to six weeks for patients who have switched from other testosterone preparations to Nebido, under observation of clinical symptoms. Ideally one ampoule of Nebido is injected deeply into the gluteal muscle slowly over a period of approximately 2 minutes. Measurement of serum trough testosterone levels and clinical symptoms should be considered for individualization of therapy with Nebido. Serum trough testosterone levels should be in the lower third of the normal range. Since steady state serum testosterone levels can be assumed to be achieved after the first six months of treatment, it appears advisable to control serum testosterone before the fourth injection (usual spacing between administrations provided).
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Packaging Details: "Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark."
Yes! I am Interested

Scapho (Secukinumab 150 Mg)

Scapho (Secukinumab 150 Mg)
  • Scapho (Secukinumab 150 Mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Vial
ManufacturerNovartis Healthcare Pvt. Ltd
Dose150 Mg
Packaging TypeBottle
BrandSCAPHO
CompositionSecukinumab 150 Mg
Packaging Size1 Vial

SCAPHO (Secukinumab 150 Mg) Injection is an interleukin inhibitor used for the treatment of moderate to severe plaque psoriasis (a skin disease characterized by red, scaly patches on some areas of the body) in adults patients, where the systemic therapy is appropriate. It is also used to treat active psoriatic arthritis and active ankylosing spondylitis in adults. This medicine is not recommended for use in patients below 18 years of age.DosageMissed DoseSince this medicine is administered by a qualified healthcare professional in the clinical or hospital setting, the likelihood of a missed dose is very low. If you miss an appointment for a scheduled dose of this medicine, contact your doctor immediately for further instructions.OverdoseSince this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
Side effectsMajor & minor side effects for Scapho InjectionHeadacheMuscle painFeverChillsCoughUnusual tiredness or weaknessRunny NoseSore throatEar congestionItching or skin rashFast heartbeatSevere stomach painDizziness
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Inform the doctor if you have a known history of allergy to this medicine. Report to the doctor all your current medicines including any herbs and supplements as well as your medical conditions before receiving this medicine. Consult your doctor immediately if you develop any signs and symptoms of an infection.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

BEOVU (Brolucizumab-Dbll 6mg)

BEOVU  (Brolucizumab-Dbll 6mg)
  • BEOVU  (Brolucizumab-Dbll 6mg)
  • BEOVU  (Brolucizumab-Dbll 6mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Vial
Packaging TypeVial
Drug NameBrolucizumab-Dbll
Packaging SizeBottle
BrandBEOVU
DoseTake BEOVU vial only as per the dose and duration suggested by your doctor
Usage/ApplicationNeovascular
Dose/Strength6mg

BEOVU (brolucizumab-dbll 6mg) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS BEOVU is contraindicated in patients with ocular or periocular infections, active intraocular inflammation or known hypersensitivity to brolucizumab or any of the excipients in BEOVU. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation. WARNINGS AND PRECAUTIONS Endophthalmitis and Retinal Detachment Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection techniques must always be used when administering BEOVU. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Retinal Vasculitis and/or Retinal Vascular Occlusion Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of BEOVU. Patients should be instructed to report any change in vision without delay. Increase in Intraocular Pressure Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection including with BEOVU. Sustained IOP increases have also been reported. Both IOP and perfusion of the optic nerve head must be monitored and managed appropriately. Thromboembolic Events Although there was a low rate of arterial thromboembolic events (ATEs) observed in the BEOVU clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The ATE rate in the two controlled 96-week neovascular AMD studies (HAWK and HARRIER) during the first 96-weeks was 4.5% (33 of 730) in the pooled brolucizumab arms compared with 4.7% (34 of 729) in the pooled aflibercept arms. ADVERSE REACTIONS Serious adverse reactions including endophthalmitis, retinal detachment, retinal vasculitis and/or retinal vascular occlusion, increases in intraocular pressure, and arterial thromboembolic events have occurred following intravitreal injections with BEOVU. The most common adverse events (≥5% of patients) with BEOVU were vision blurred, cataract, conjunctival hemorrhage, vitreous floaters and eye pain. As with all therapeutic proteins, there is a potential for an immune response in patients treated with BEOVU. Anti-brolucizumab antibodies were detected in the pre-treatment sample of 36% to 52% of treatment naive patients. After initiation of dosing, anti-brolucizumab antibodies were detected in at least one serum sample in 53% to 67% of patients treated with BEOVU. Intraocular inflammation was observed in 6% of patients with anti-brolucizumab antibodies detected during dosing with BEOVU. The significance of anti-brolucizumab antibodies on the clinical effectiveness and safety of BEOVU is not known.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested
X

Explore More Product

View All Product


Reach Us
Rakshit Jain (Sales & Marketing Manager)
Bull Pharmachem
No. 64C, Dhan Sadan Co Operative Housing Society, 2nd Floor
Kalbadevi, Mumbai - 400002, Maharashtra, India


Call Us


Send E-mail